Platelet function in rheumatoid arthritis: Arthritic and cardiovascular implications

Rheumatology International

Volumn 31, Issue 2, 2011, Pages 153-164

  Gasparyan, Armen Yuri ^a   Stavropoulos Kalinoglou, Antonios ^a   Mikhailidis, Dimitri P ^b   Douglas, Karen M J ^a   Kitas, George D ^a,c  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomarkers; Cardiovascular risk; Inflammation; Platelet function; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; BETA THROMBOGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CD63 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PHOSPHOLIPASE A2; SALAZOSULFAPYRIDINE; THROMBOCYTE FACTOR 4; THROMBOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INTERACTION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MEGAKARYOPOIESIS; OBESITY; PATHOGENESIS; PLATELET MICROPARTICLE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; THROMBOSIS;

ANTIGENS, CD40; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CELL-DERIVED MICROPARTICLES; HUMANS; P-SELECTIN; THROMBOSIS;

EID: 79954436381     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-010-1446-x     Document Type: Review

References (105)

1. Alamanos Y, Voulgari PV, Drosos AA (2006) Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36:182-188 (Pubitemid 44691887)
2. Gabriel SE (2008) Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 121 (10 Suppl 1): S9-S14
3. Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862-873 (Pubitemid 34303796)
4. DeMaria AN (2002) Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 89 (6 A): 33D-38D (Pubitemid 34241486)
5. Kitas GD, Erb N (2003) Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42:607-613 (Pubitemid 37220867)
6. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (In press)
7. Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36-40 (Pubitemid 36077769)
8. Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE (2006) Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 54:60-67 (Pubitemid 43122187)
9. Lip GY, Gibbs CR (1999) Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 33:1424-1426
10. Ahnert AM, Freudenberger RS (2008) What do we know about anticoagulation in patients with heart failure? Curr Opin Cardiol 23:228-232 (Pubitemid 351489325)
11. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737-2745 (Pubitemid 34016192)
12. Szekanecz Z, Koch AE (2008) Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 10:224
13. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957-2963 (Pubitemid 37553561)
14. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD (2005) Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 7:1-24
15. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1:338-347 (Pubitemid 38340246)
16. Montecucco F, Mach F (2009) Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 48:11-22
17. Palmer DG, Hogg N, Revell PA (1986) Lymphocytes, polymorphonuclear leukocytes, macrophages and platelets in synovium involved by rheumatoid arthritis. A study with monoclonal antibodies. Pathology 18:431-437 (Pubitemid 17231354)
18. Farr M, Wainwright A, Salmon M, Hollywell CA, Bacon PA (1984) Platelets in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 4:13-17 (Pubitemid 14167216)
19. Endresen GK (1989) Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 9:19-24 (Pubitemid 19176934)
20. Endresen GK, Førre O (1992) Human platelets in synovial fluid. A focus on the effects of growth factors on the inflammatory responses in rheumatoid arthritis. Clin Exp Rheumatol 10:181-187
21. Endresen GK (1981) Investigation of blood platelets in synovial fluid from patients with rheumatoid arthritis. Scand J Rheumatol 10:204-208 (Pubitemid 11004923)
22. Schmitt-Sody M, Klose A, Gottschalk O, Metz P, Gebhard H, Zysk S, Eichhorn ME, Hernandez-Richter TM, Jansson V, Veihelmann A (2005) Platelet-endothelial cell interactions in murine antigen-induced arthritis. Rheumatology (Oxford) 44:885-889 (Pubitemid 41511183)
23. Schmitt-Sody M, Metz P, Gottschalk O, Birkenmaier C, Zysk S, Veihelmann A, Jansson V (2007) Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets 18:365-372 (Pubitemid 47123839)
24. Schmitt-Sody M, Metz P, Klose A, Gottschalk O, Zysk S, Hausdorf J, Veihelmann A, Jansson V (2007) In vivo interactions of platelets and leucocytes with the endothelium in murine antigen-induced arthritis: the role of P-selectin. Scand J Rheumatol 36:311-319 (Pubitemid 47346919)
25. Waguri-Nagaya Y, Otsuka T, Sugimura I, Matsui N, Asai K, Nakajima K, Tada T, Akiyama S, Kato T (2000) Synovial inflammation and hyperplasia induced by gliostatin/plateletderived endothelial cell growth factor in rabbit knees. Rheumatol Int 20:13-19
26. Shapleigh C, Valone FH, Schur PH, Goetzl EJ, Austen KF (1980) Platelet-activating activity in synovial fluids of patients with rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and noninflammatory arthropathies. Arthritis Rheum 23:800-807 (Pubitemid 10076972)
27. Weissbarth E, Baruth B, Mielke H, Liman W, Deicher H (1982) Platelets as target cells in rheumatoid arthritis and systemic lupus erythematosus: a platelet specific immunoglobulin inducing the release reaction. Rheumatol Int 2:67-73 (Pubitemid 12023791)
28. Jagroop IA, Kakafika AI, Mikhailidis DP (2007) Platelets and vascular risk: an option for treatment. Curr Pharm des 13:1669-1683 (Pubitemid 46979721)
29. Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339-3347 (Pubitemid 43121817)
30. Harrison P, Goodall AH (2008) "Message in the platelet"-more than just vestigial mRNA! Platelets 19:395-404
31. Lerkevang Grove E, Hvas AM, Dalby Kristensen S (2009) Immature platelets in patients with acute coronary syndromes. Thromb Haemost 101:151-156
32. Davì G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482-2494
33. Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N (2008) Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets 19:146-154 (Pubitemid 351302382)
34. Yetkin e (2008) Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb Haemost 100:3-4 (Pubitemid 351948736)
35. Bath PM, Butterworth RJ (1996) Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 7:157-161 (Pubitemid 26167943)
36. Boos CJ, Lip GY (2007) Assessment of mean platelet volume in coronary artery disease-what does it mean? Thromb Res 120:11-13 (Pubitemid 46601581)
37. Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP (2000) Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets 11:28-32 (Pubitemid 30201162)
38. Javela K, Kekomäki R (2007) Mean platelet size related to glycoprotein-specific autoantibodies and platelet-associated IgG. Int J Lab Hematol 29:433-441 (Pubitemid 350060623)
39. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP (2003) Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 9:177-190 (Pubitemid 37070125)
40. Avramakis G, Papadimitraki E, Papakonstandinou D, Liakou K, Zidianakis M, Dermitzakis A, Mikhailidis DP, Ganotakis ES (2007) Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets 18:16-23
41. Muscari A, De Pascalis S, Cenni A, Ludovico C, Castaldini N, Antonelli S, Bianchi G, Magalotti D, Zoli M (2008) Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost 99:1079-1084 (Pubitemid 351810490)
42. Colkesen Y, Acil T, Abayli B, Yigit F, Katircibasi T, Kocum T, Demircan S, Sezgin A, Ozin B, Muderrisoglu H (2008) Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinolysis 19:411-414
43. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R (2002) Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 117:399-404 (Pubitemid 34451156)
44. Martin JF, Bath PM, Burr ML (1991) Influence of platelet size on outcome after myocardial infarction. Lancet 338:1409-1411
45. Bath P, Algert C, Chapman N, Neal B (2004) PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 35:622-626 (Pubitemid 38280830)
46. Coban E, Adanir H (2008) Platelet activation in patients with familial Mediterranean fever. Platelets 19:405-408
47. Milovanovic M, Nilsson E, Järemo P (2004) Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 343:237-240 (Pubitemid 38534523)
48. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, Kiraz S, Ertenli I, Calguneri M (2008) Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 75:291-294
49. Ertenli I, Kiraz S, Oztürk MA, Haznedaroǧlu I, Celik I, Calgüneri M (2003) Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 23:49-60 (Pubitemid 36384721)
50. Farr M, Scott DL, Constable TJ, Hawker RJ, Hawkins CF, Stuart J (1983) Thrombocytosis of active rheumatoid disease. Ann Rheum Dis 42:545-549 (Pubitemid 13016027)
51. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA (2001) Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 96:776-781 (Pubitemid 32240730)
52. Barradas MA, Stansby G, Hamilton G, Mikhailidis DP (1994) Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol 13:202-207 (Pubitemid 24295718)
53. Fink PC, Piening U, Fricke PM, Deicher H (1979) Platelet aggregation and aggregation inhibition by different antiglobulins and antiglobulin complexes from sera of patients with rheumatoid arthritis. Arthritis Rheum 22:896-903 (Pubitemid 10162665)
54. Saeed SA, Gilani AH, Rasheed H, Bhatti FN, Atiq M, Qureshi A, Jafary R, Connor JD (2002) Plasma from rheumatoid patients taking low dose methotrexate enhances platelet aggregation. Res Commun Mol Pathol Pharmacol 111:69-76 (Pubitemid 37214203)
55. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA (2002) Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 41:458-461 (Pubitemid 34537847)
56. Alcalay M, Bontoux D, Peltier A, Vial MC, Vilde JM, Wautier JL (1981) C7 deficiency, abnormal platelet aggregation, and rheumatoid arthritis. Arthritis Rheum 24:102-103
57. Falus A, Merétey K, Bagdy D, Diószegi M, Böhm U, Csák E, Bozsóky S (1982) Beta-2-microglobulin-specific autoantibodies cause platelet aggregation and interfere with ADP-induced aggregation. Clin Exp Immunol 47:103-109 (Pubitemid 12251287)
58. Riddle JM, Bluhm GB, Pitchford WC, McElroy H, Jimenea C, Leisen J, Venkatasubramanian K (1981) A comparative study of platelet reactivity in arthritis. Ann N Y Acad Sci 370:22-29 (Pubitemid 11049614)
59. Colli S, Maderna P, Tremoli E, Colombo F, Canesi B (1982) Platelet function in rheumatoid arthritis. Scand J Rheumatol 11:139-143 (Pubitemid 12030866)
60. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL (1997) A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 36:164-169
61. Sfikakis PP, Charalambopoulos D, Vaiopoulos G, Mavrikakis M (1999) Circulating P-and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol 18:28-32 (Pubitemid 29104749)
62. Meyer MF, Schmidt O, Hellmich B, Schatz H, Klein HH, Braun J (2007) Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations. Rheumatol Int 28:145-152 (Pubitemid 350105865)
63. Li G, Sanders JM, Phan ET, Ley K, Sarembock IJ (2005) Arterial macrophages and regenerating endothelial cells express P-selectin in atherosclerosis-prone apolipoprotein E-deficient mice. Am J Pathol 167:1511-1518 (Pubitemid 41713306)
64. Frenette PS, Wagner DD (1996) Adhesion molecules: part II. Blood vessels and blood cells. N Engl J Med 335:43-45 (Pubitemid 26230813)
65. Chung I, Lip GY (2003) Virchow's triad revisited: blood constituents. Pathophysiol Haemost Thromb 33:449-454 (Pubitemid 40278723)
66. von Hundelshausen P, Weber C (2007) Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100:27-40 (Pubitemid 46066771)
67. McNicol A, Israels SJ (2008) Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets 8:99-117
68. Sumariwalla PF, Malfait AM, Feldmann M (2004) P-selectin glycoprotein ligand 1 therapy ameliorates established collageninduced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor. Clin Exp Immunol 136:67-75 (Pubitemid 38437767)
69. Ertenli I, Kiraz S, Arici M, Haznedaroglu IC, Calgüneri M, Celik I, Kirazli S (1998) P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol 25:1054-1058 (Pubitemid 28350874)
70. Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Davis RC, Lip GY (2009) Plasma indices of endothelial and platelet activation in rheumatoid disease: relationship to cardiovascular co-morbidity. Int J Cardiol 134:97-103
71. Ateş A, Kinikli G, Turgay M, Duman M (2004) Serum-soluble selectin levels in patients with rheumatoid arthritis and systemic sclerosis. Scand J Immunol 59:315-320 (Pubitemid 38429299)
72. Bunescu A, Seideman P, Lenkei R, Levin K, Egberg N (2004) Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 31:2347-2355 (Pubitemid 39603080)
73. Hagberg IA, Lyberg T (2000) Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies. Platelets 11:137-150 (Pubitemid 30345421)
74. Klinkhardt U, Harder S (2005) Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function? Semin Thromb Hemost 31:400-403 (Pubitemid 41362344)
75. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ (2001) Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 115:451-459 (Pubitemid 34203516)
76. Matzdorff A (2005) Platelet function tests and flow cytometry to monitor antiplatelet therapy. Semin Thromb Hemost 31:393-399 (Pubitemid 41362343)
77. Wang F, Wang NS, Yan CG, Li JH, Tang LQ (2007) The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol 26:768-771 (Pubitemid 46554089)
78. de Man FH, Nieuwland R, van der Laarse A, Romijn F, Smelt AH, Gevers Leuven JA, Sturk A (2000) Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy. Atherosclerosis 152:407-414
79. Preston RA, Coffey JO, Materson BJ, Ledford M, Alonso AB (2007) Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension. Atherosclerosis 192:148-154 (Pubitemid 46602291)
80. Chung I, Choudhury A, Patel J, Lip GY (2009) Soluble, plateletbound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 41:45-51
81. Koyama H, Maeno T, Fukumoto S, Shoji T, Yamane T, Yokoyama H, Emoto M, Shoji T, Tahara H, Inaba M, Hino M, Shioi A, Miki T, Nishizawa Y (2003) Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 108:524-529 (Pubitemid 36961164)
82. Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA (2002) Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 46:1498-1503 (Pubitemid 34620195)
83. Ardoin SP, Shanahan JC, Pisetsky DS (2007) The role of microparticles in inflammation and thrombosis. Scand J Immunol 66:159-165 (Pubitemid 47063209)
84. Berckmans RJ, Nieuwland R, Tak PP, Böing AN, Romijn FP, Kraan MC, Breedveld FC, Hack CE, Sturk A (2002) Cellderived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 46:2857-2866 (Pubitemid 35315876)
85. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591-594 (Pubitemid 28157601)
86. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A (1998) Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 28:2760-2769 (Pubitemid 28425234)
87. Sallusto F, Mackay CR (2004) Chemoattractants and their receptors in homeostasis and inflammation. Curr Opin Immunol 16:724-731 (Pubitemid 39423660)
88. Kim KW, Cho ML, Kim HR, Ju JH, Park MK, Oh HJ, Kim JS, Park SH, Lee SH, Kim HY (2007) Up-regulation of stromal cellderived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 56:1076-1086
89. Kyburz D, Corr M, Brinson DC, Von Damm A, Tighe H, Carson DA (1999) Human rheumatoid factor production is dependent on CD40 signaling and autoantigen. J Immunol 163:3116-3122 (Pubitemid 29431809)
90. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps TJ, Hashimoto H (2001) Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 28:2583-2590 (Pubitemid 33135639)
91. McLaren M, Waring A, Galarraga B, Rudd A, Morley K, Belch JJ (2005) Investigation of platelet glycoprotein IIIa polymorphism using flow cytometry in patients with rheumatoid arthritis. Scand J Rheumatol 34:437-440 (Pubitemid 43062197)
92. Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE (2006) Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther 8: R81
93. Weicht B, Maitz P, Kandler B, Fischer MB, Watzek G, Gruber R (2007) Activated platelets positively regulate RANKL-mediated osteoclast differentiation. J Cell Biochem 102:1300-1307 (Pubitemid 350220050)
94. Mattey DL, Nixon N, Dawes PT, Kerr J (2005) Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann Rheum Dis 64:1190-1194 (Pubitemid 41113355)
95. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8: R151
96. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173-1177 (Pubitemid 34304256)
97. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M (2008) Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 31:175-179
98. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM, Martin J, Dessein PH, Llorca J (2008) Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 26:311-316 (Pubitemid 351659139)
99. Trocmé C, Marotte H, Baillet A, Pallot-Prades B, Garin J, Grange L, Miossec P, Tebib J, Berger F, Nissen MJ, Juvin R, Morel F, Gaudin P (2009) Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 68:1328-1333
100. Astbury C, Platt R, Dixon JS, Le Gallez P, Hill J, Bird HA (1993) Optimizing the assessment of disease activity during treatment with anti-rheumatoid drugs. Br J Rheumatol 32:467-473 (Pubitemid 23193402)
101. Veale DJ, Maple C, Kirk G, McLaren M, Belch JJ (1998) Soluble cell adhesion molecules-P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol 27:296-299 (Pubitemid 28416987)
102. Espinola RG, Pierangeli SS, Gharavi AE, Harris en (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87:518-522 (Pubitemid 34232495)
103. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:72-75 (Pubitemid 350286266)
104. Maitz P, Kandler B, Fischer MB, Watzek G, Gruber R (2006) Activated platelets retain their potential to induce osteoclast-like cell formation in murine bone marrow cultures. Platelets 17:477-483 (Pubitemid 44665571)
105. Gasparyan AY, Stavropoulos-Kalinoglou A, Toms TE, Douglas KM, Kitas GD (2010) Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm Allergy Drug Targets 9:45-50